Highlights

  • Anteris completed a USD 320 million combined public offering and private placement to support DurAVR THV trials.
  • Medtronic made a USD 90 million strategic investment, aligning on TAVR innovation and long-term patient outcomes.
  • The capital raise will fund global pivotal PARADIGM trial execution and expansion of manufacturing capabilities.

Anteris Technologies Global Corp (ASX:AVR) (NASDAQ:AVR) share price surged by 9.43% to AUD 9.75 on 23 January 2026, following the announcement of USD 320 million in gross proceeds raised through an underwritten public offering and a strategic private placement with Medtronic. The capital will support the company’s next growth phase, including the execution of the global pivotal PARADIGM trial and advancing the global commercialization of its DurAVR Transcatheter Heart Valve (THV).

Medtronic Investment Signals Strategic Collaboration

The USD 90 million strategic investment by Medtronic (NYSE:MDT) follows the public offering of 40,000,000 shares at USD 5.75 per share.

Medtronic’s participation brings expertise in Transcatheter Aortic Valve Replacement (TAVR) innovation and reinforces shared objectives of advancing valve science while prioritizing durability, hemodynamics, and long-term patient outcomes. Anteris and Medtronic remain aligned on enhancing clinical science and valve design, with the potential for expanded collaboration in other strategic areas.

Details of the Offering and Private Placement

The public offering included the full exercise of the underwriters’ option to purchase additional shares, resulting in a total issuance of 40,000,000 shares at USD 5.75 per share. In addition, Medtronic acquired 15,652,173 shares in a private placement at the same price.

The gross proceeds of USD 320 million, prior to underwriting discounts and estimated expenses, position Anteris to advance its clinical strategy and operational footprint. Key uses of the proceeds include recruitment and study execution for the DurAVR global pivotal trial, expansion of manufacturing capabilities, ongoing research for v2vmedtech, and general corporate purposes.

Outlook: Driving Growth and Clinical Innovation

The capital raise provides Anteris with the resources to continue executing the PARADIGM trial and advancing toward regulatory approval for DurAVR THV. The funding also allows continued investment in research and development for innovative heart valve solutions while strengthening the company’s manufacturing and operational infrastructure.